Latest news with #Sterilization
Globe and Mail
2 days ago
- Business
- Globe and Mail
Infection Control Market to Reach USD 139.94 Billion by 2030, Driven by Hospital-Acquired Infection Prevention and Sterilization Demand
"Infection Control Market" Mordor Intelligence has published a new report on the Infection Control Market offering a comprehensive analysis of trends, growth drivers, and future projections. Introduction According to a 2025 report on infection control market by Mordor Intelligence, the market is estimated at USD 102.36 billion in 2025 and is projected to reach USD 139.94 billion by 2030, growing at a CAGR of 6.45% during the forecast period The infection control market plays a crucial role in maintaining hygiene and safety standards across hospitals, laboratories, pharmaceutical production units, and life sciences facilities. Infection prevention solutions such as sterilization, disinfection, and cleaning consumables are critical to minimize risks to patients, healthcare staff, and consumers. The market growth is attributed to rising hospital-acquired infection cases, stringent guidelines to control contamination, and high demand for effective sterilization products in medical device reprocessing. Key Trends Hospital-acquired infections driving product demand The report highlights that the increasing number of hospital-acquired infections (HAIs) has made infection control a critical operational area in hospitals and clinics. These infections prolong hospital stays and increase treatment costs, making preventive sterilization, disinfectant usage, and effective waste disposal mandatory to maintain public health standards. Sterilization segment maintains dominance Sterilization remains the largest segment in the infection control market, supported by the widespread use of sterilizers in hospitals, outpatient facilities, and diagnostic labs for surgical instrument reprocessing and equipment sterilization. Within sterilization, the use of low-temperature sterilizers is increasing to protect heat-sensitive instruments. Disinfectants witnessing rising application Disinfectants are used extensively for surface cleaning, floor cleaning, and equipment cleaning in critical care units and operating theatres. The trend of ready-to-use disinfectant wipes, sprays, and solutions is growing due to convenience and time efficiency in hospitals and diagnostic centres. Pharmaceutical and life sciences sector driving demand Beyond hospitals, pharmaceutical manufacturing units, research laboratories, and biotechnology firms require advanced contamination control. The demand for cleanrooms and sterile processing areas contributes significantly to market expansion in the infection control segment. North America remains the largest market According to the Mordor Intelligence report, North America continues to hold the largest market share driven by the high number of surgeries performed annually, better healthcare infrastructure, and stringent infection control regulations by organizations such as the CDC and FDA. Market Segmentation The infection control market report segments the industry into Product, Service Delivery Mode, End User and Geography. By Product Sterilization Products and Services: Includes equipment such as autoclaves and low-temperature sterilizers, along with contract sterilization services. These solutions ensure medical devices and surgical instruments are free from viable microorganisms before reuse. Cleaning and Disinfection Products: Encompasses disinfectant liquids, sprays, wipes, and detergents used for cleaning surfaces, instruments, and hospital environments to reduce contamination risks. Protective Barriers: Includes gloves, gowns, face masks, and drapes used by healthcare professionals to prevent cross-contamination during surgical or diagnostic procedures. By Service Delivery Mode In-house Infection Control: Refers to infection prevention and control activities managed within healthcare facilities, pharmaceutical manufacturing units, and laboratories using their own sterilization equipment, disinfectants, and staff. Hospitals and large medical centres often maintain in-house sterilization departments to handle equipment reprocessing and facility hygiene efficiently without outsourcing. Contract Infection Control: Outsourcing sterilization and contamination control services to third-party providers. This is widely used by medical device manufacturers and pharmaceutical companies that require large-scale sterilization but prefer specialized contract service providers to ensure regulatory compliance, cost efficiency, and access to advanced sterilization technologies without heavy capital investments. Hospitals and Clinics: The largest segment, driven by the constant need for sterilization and disinfection in surgical theatres, ICUs, OPDs, and diagnostic labs to prevent healthcare-associated infections. Medical Device Companies: Use sterilization services and equipment for manufacturing sterile medical products and packaging to comply with international quality and safety standards. Pharmaceutical and Life Sciences Companies: Require stringent contamination control and sterilization solutions in production lines, cleanrooms, and research facilities to ensure product safety and regulatory compliance. Pharmaceutical and Biologics Manufacturers: These include companies involved in producing pharmaceutical drugs, vaccines, and biologic products. They require stringent sterilization, contamination control, and cleanroom hygiene practices throughout manufacturing to ensure product safety, efficacy, and compliance with global regulatory standards. Life-Science and Food-Processing Facilities: Facilities engaged in life sciences research, diagnostics, and food processing depend on infection control measures to maintain sterile environments, prevent cross-contamination, and uphold product quality and safety during processing, packaging, and storage operations. Ambulatory Surgery Centers: These are outpatient surgical facilities that perform procedures not requiring hospital admission. Infection control practices such as equipment sterilization, use of disinfectants, and protective barriers are critical to ensure patient safety and prevent surgical site infections in these high-throughput environments. By Geography North America: Largest market with well-established infection control guidelines. Europe: Growing due to increased healthcare spending and focus on patient safety. Asia-Pacific: Expected to witness the fastest growth owing to rising surgical procedures, healthcare infrastructure development, and increasing awareness. Middle East & Africa: Growth driven by improving healthcare systems and infection prevention investments. South America: Developing market with gradual adoption of stringent infection control standards. Key Players The infection control market report identifies key companies providing sterilization, disinfection, and protective barrier solutions. Fortive (Advanced Sterilization Products): Advanced Sterilization Products (ASP) is a part of Fortive Corporation. ASP is known for providing infection prevention solutions, particularly focusing on sterilization and disinfection products used in hospitals and healthcare facilities. 3M Company: Offers a wide range of infection prevention products including sterilization assurance, hand hygiene, and barrier solutions catering to hospitals globally. Steris Corporation: Known for its sterilization equipment, instrument reprocessing products, and infection prevention consumables for healthcare and life sciences sectors. Getinge AB: Provides sterilizers, washer-disinfectors, and associated consumables with a strong market presence in hospital sterile processing departments. Cantel Medical Corp: Specializes in endoscope reprocessing systems, high-level disinfectants, and infection control consumables supporting GI and surgical care. These companies focus on expanding their infection prevention product portfolios through strategic acquisitions, product launches, and partnerships with hospitals, labs, and pharmaceutical companies to address growing infection control needs. Conclusion The infection control market is set for robust growth, with a projected value of USD 139.94 billion by 2030. Rising cases of hospital-acquired infections, expanding surgical procedures, and increasing contamination control requirements in pharmaceuticals and life sciences will continue to support market expansion. While North America remains dominant, Asia-Pacific is expected to witness the fastest growth in the coming years due to healthcare infrastructure development and heightened awareness regarding infection control practices. Companies investing in product innovation and strategic collaborations are well-positioned to meet evolving hospital, laboratory, and industrial hygiene demands. Industry Related Reports Dental Infection Control Market: The dental infection control market is segmented by Product Type (Equipment and Consumables), End User (Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report provides the value (in USD million) for these segments. Surgical Site Infection Control Market : Surgical Site Infection Control Market: is segmented by Product (Manual Preprocessors Solution, Disinfectants, and more), Surgery/Procedure (Cataract Surgery, Cesarean Section, and more), Type of Infection (Superficial Incisional SSI, and more), End User (Hospitals, and more), and Geography (North America, Europe, and more). The report provides the value (in USD million) for these segments. Get More Insights: Infection surveillance solutions market : Infection Surveillance Solutions Market is segmented by Type (Surgical-Site Infections, Blood-Stream Infections, Catheter-Associated UTIs, and Ventilator-Associated Pneumonia), Offering (Software and Services), Deployment Model (On-Premises and Cloud), End User (Hospitals, Long-Term Care Facilities, Ambulatory Surgery Centers, and more), and Geography. The report provides the market forecasts in terms of value (USD). About Mordor Intelligence: Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics. For any inquiries or to access the full report, please contact: media@
Yahoo
19-02-2025
- Health
- Yahoo
Chlorine Dioxide Debuts in Updated Standards for Healthcare Sterilants and High-Level Disinfectants
Unique foam and wipe system offers fast, efficient, and economical high-level disinfection for ultrasound transducers and probes FAIRFIELD, N.J., Feb. 19, 2025 /PRNewswire/ -- An updated standard compiled by the Association for the Advancement of Medical Instrumentation (AAMI) and adopted by the American National Standards Institute (ANSI) has acknowledged chlorine dioxide foam as a novel modality for high-level disinfection of medical devices. The updated standard for the US market echoes a 2024 update of guidelines from the World Federation for Ultrasound in Medicine and Biology, which included chlorine dioxide in its instructions for the cleaning and disinfection of endocavitary ultrasound probes. The newly revised AAMI standard, Chemical Sterilization and High-Level Disinfection in Health Care Facilities (ANSI/AAMI ST58:2024), replaces previous versions and provides guidance on FDA-cleared liquid chemical sterilants, high-level disinfectants, and gaseous chemical sterilizers. It is intended as a guide for professionals in hospitals, labs, and other healthcare facilities. Among the changes incorporated in the revised standard is the recognition of a residue removal step as defined in the instructions for use of chlorine dioxide foam. Historically, rinsing with water was the only option recommended under the standard. Now, the use of other residue removal procedures defined by the manufacturer has been recognized and included as an alternative solution. According to AAMI, adopting and implementing ST58 will be critical for preventing healthcare-associated infections. Healthcare professionals can use the updated document to protect patients and demonstrate conformance with best practices. Chlorine Dioxide in US Healthcare Settings Parker Laboratories manufactures and distributes chlorine dioxide foam products for US healthcare markets under an exclusive commercial partnership with UK-based Tristel plc (AIM: TSTL). The company's Tristel ULT is a formulation that uses a proprietary foam and wipes to perform high-level disinfection and residue removal for ultrasound transducers. Tristel ULT received FDA De Novo clearance in June 2023, creating a new category of Class II devices with the generic name 'foam or gel chemical sterilant/high-level disinfectant' intended for use as the final step in high-level disinfection (HLD) of medical devices prior to patient use. Although chlorine dioxide is relatively new to US healthcare markets, the compound has a decades-long history of use in overseas markets. As a high-level disinfectant, Tristel ULT has been tested for efficacy against bacteria, fungi, mycobacteria, and viruses. In studies involving clinically relevant microbes, Tristel ULT was found to be capable of eradicating a wide range of pathogens, including Candida albicans, hepatitis viruses A, B, and C; human immunodeficiency virus (HIV); human papillomavirus (HPV) types 16 and 18; and Mycobacterium terrae (a surrogate for M. tuberculosis). In addition, Tristel ULT passed the AOAC International sporicidal activity test. "Asepsis is paramount in infection prevention, especially when we know that up to 60% of central line-associated bloodstream infections are linked to skin flora," says infection prevention expert Constance J. Cutler, MS, BS, BSN, CIC, FSHEA, FAPIC. "Prioritizing patient safety means implementing disinfection strategies that are both effective and efficient. The proven performance of chlorine dioxide in reducing microbial contamination presents a strong business case for its adoption, offering a reliable solution that aligns with both clinical and operational goals." Key Advantages Tristel ULT is delivered in a novel dosing bottle with two separate compartments. One compartment contains the Tristel Part A solution (sodium chlorite) and the other contains the Tristel Part B solution (citric acid). When the pump is pressed, the two solutions mix, generating a precise and consistent dose of chlorine dioxide foam. Compatible with more than 1000 transducer models, Tristel ULT offers advantages over competing HLD products that can make it especially suited for use in a wide variety of clinical settings: Rapid Action. Tristel ULT achieves high-level disinfection quickly, reducing device turnaround time in high-volume, fast-paced healthcare settings. Easy to Use. The application process includes a manufacturer-defined residue removal step, now formally recognized by AAMI, improving workflow efficiency. Cost-Effective. Tristel ULT's ease of use eliminates the need for expensive automated systems, making it accessible for facilities of all sizes. Portable and Practical. Requiring no electricity or water, Tristel ULT is both compact and portable—ideal for point-of-care device processing in all healthcare settings, and particularly for remote or resource-limited locations. "Adopting Tristel ULT has enabled us to better allocate the clinic staff's time to patient care," says Matthew Allaway, MD, a urologist with Urology Associates (Cumberland, MD), and founder and CEO of the medical device company, Perineologic. "As a result, we have increased the number of life-saving procedures we can perform during a typical workday. These efficiencies have improved the overall efficiency of our practice and reduced unnecessary costs and waste." As healthcare facilities continue to seek faster and more-effective solutions for high-level disinfection, the adoption of chlorine dioxide foam has gained momentum worldwide. "Having seen the positive impacts of point-of-care high-level disinfection using chlorine dioxide foam at clinical sites using the ExactVu Micro-Ultrasound System in Europe, Exact Imaging applauds AAMI's guideline update," says Randy AuCoin, president and CEO of Exact Imaging (Markham, ON, Candada). "The Tristel ULT product is validated for use with our EV29L transducer and has already helped many practices safely increase their throughput to provide better care to more patients with micro-ultrasound." Other vendors have developed a method for generating chlorine dioxide in a gaseous formulation that is gentle on materials and is an EPA-registered sterilant. Interest in this formulation has grown recently because of its potential as a safer method for sterilizing medical products, replacing both ethylene oxide and gamma irradiation. Information about the use of chlorine dioxide as a sterilant is now included in an AAMI technical information report, Compatibility of Materials Subject to Sterilization (AAMI TIR17:2024), which is intended to help manufacturers qualify materials for use in products requiring sterilization. About Parker Laboratories Parker Laboratories is a leading global medical product company that develops, manufactures, and sells ultrasound and electromedical contact media and accessories, as well as leading lines of instrument cleaners and disinfectants. A worldwide leader in ultrasound medical products for over 65 years, Parker has consistently been at the forefront of technological advances in the industry. Its flagship product, Aquasonic 100 ultrasound transmission gel, is the world standard for medical ultrasound. For more information, visit Additional Resources Tristel ULT Product Backgrounder Tristel ULT Features and Benefits Tristel ULT Device Compatibility Summary Contact: Liz Dowling760/822-3412liz@ Steve Halasey626/355-2500steve@ and Dennis Public Relations View original content to download multimedia: SOURCE Parker Laboratories Sign in to access your portfolio
